一分钟看懂
这是一项关于胃癌的I 期研究，登记的药物或干预包括KD-496，当前状态为招募中。登记地点显示中国北京有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
KD-496 · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer Hospital · 北京
公开的入选条件
- 1. Subjects fully understand the study and voluntarily sign informed consent；
- 2. Age 18 to 75 years old (including 75 years old), male and female；
- 3. Patients diagnosed with advanced solid tumors by histopathology or cytology and failed at least 2 prior lines treatment; preferentially enrolled in gastric cancer, pancreatic cancer, etc. Standard treatment recommendations refer to the latest version of the
- 4. Immunohistochemistry confirmed that NKG2DL/CLDN18.2 was positive (the sum of NKG2DL and CLDN18.2 positive scores ≥5 according to the principle of positive comprehensive score 0\~12 points).Tissue specimens for IHC testing must be obtained within 1 year prio
- 5. Subjects must have measurable lesions as defined by the RECIST v1.1 standard;
- 6. ECOG physical status score 0 to 1;
- 7. Estimated life expectancy ≥ 3 months;
- 8. Subjects must have adequate peripheral venous access for peripheral blood mononuclear cell (PBMC) collection;
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06134960；登记信息更新于 2026-09-14。